Pain: Novel Analgesics from Traditional Chinese Medicines  by Ingram, Susan L.
Current Biology Vol 24 No 3
R114underlying the generation of head
direction cell directional firing
properties. Head direction cells
are generally thought to comprise
recurrently connected one-dimensional
attractor networks [10] in which the
cells have similar connectivities; tuning
width gradations do not emerge
naturally from such self-organising
networkmodels. In order to understand
how such gradation could arise, it will
be important to determine whether
the more broadly tuned cells differ
in intrinsic membrane properties
or synaptic plasticity profiles, whether
the difference in tuning is extrinsic
and results from a difference in inputs,
or whether the differently tuned cell
types actually belong to different
subnetworks, each of which is
internally consistent, which are
differentially distributed across the
dorso-ventral extent of MEC.
What might be the adaptive
advantage of spatial encoding
gradients in the spatial system? It has
been suggested that variably-sized
place fields might allow the
representation of different sized
environments [2]; navigating around
the house is different from navigating
across town, or across the country, and
might require maps of different scales.
If scale were the relevant factor,
however, then we might expect to see
scaling relative to body size — large
grids in adults and small in infants;
large scales in rats and small in mice,
and so on. In fact, grid scales so far
seem fairly constant across
developmental stages [11,12] and
across species [13,14]. Also, the
notion of scale does not apply in the
head direction system in which there
are always only 360 degrees of
direction no matter how large the
environment.
An alternative (albeit related)
possibility, therefore, is that the
relevant difference is one of
resolution — small fields and tight
directional tuning might be used where
a high degree of precision is required,
while large fields and coarse directional
tuning might be used where the
specifics of location/direction are less
critical and the important processing
concerns the environment as a whole
(‘‘this field is dangerous’’ versus
‘‘I buried my food here’’). This
association of environments with more
generalised properties such as valence
may explain why the ventral regions
of the entorhinal-hippocampal system,where the low-resolution maps are,
are also the regions less intensely
connected to sensory areas and more
richly imbued with subcortical
connections to emotional/motivational
systems [15,16]. Being able to defocus
the map means that information that
is relevant across an environment
can be efficiently associated with it
using a smaller number of neurons.
In summary, then, the current
findings extend observations of
dorso-ventral spatial gradients in the
entorhinal-hippocampal system from
linear to angular domains. These
findings raise questions about both
the cause and consequence of such
gradients, and suggest that the brain
makes a multiplicity of maps for a
variety of settings.References
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Traditional Chinese MedicinesThe search for analgesics with fewer side effects and less abuse potential has
had limited success. A recent study identifies an analgesic alkaloid compound
from Corydalis yanhusuo, a traditional Chinese medicinal herb that has a
surprising mechanism of action.Susan L. Ingram
Opioids are the gold standard for the
treatment of severe acute and chronic
pain, but they induce undesirable side
effects and drug addiction in many
patients. The search for efficacious
pain relievers for both acute andchronic pain that do not produce
tolerance or dependence has been
essentially futile, with few candidates
that have been successful in clinical
trials. Thus, identification of novel pain
therapeutics has been the basis of
research and design programs for drug
companies for many years. The lack of
Dispatch
R115effective pain relievers has led to a
dramatic increase in the use of
complementary and alternative
medicine [1], and an increase in interest
in traditional Chinese medicine (TCM).
TCMs, including Chinese herbal
medicines, have been used in Asian
countries for thousands of years to
treat diseases. Recently, an effort
to understand the mechanisms of TCM
treatments has led to the development
of the ‘herbalome’, a database
and research library of effective
compounds extracted from medicinal
plants [2]. New advances in separation
techniques are allowing extraction and
purification of lipids, carbohydrates
and polar compounds that could not be
effectively isolated previously [2]. A
new study by Zhang and colleagues [3]
reported in a recent issue of Current
Biology used a reverse pharmacology
approach to screen fractionated
samples from 10 TCMs known for their
analgesic properties. The samples
were tested for their ability to activate
the receptor that mediates the
analgesic effects of opioids — the
mu-opioid receptor. Isolation and
purification of an active component
identified the alkaloid compound
dehydrocorybulbine (DHCB) from
Corydalis yanhusuo. Surprisingly,
DHCB is only marginally effective at
opioid receptors, but induces potent,
dose-dependent antinociception at
non-sedative doses that is insensitive
to the opioid antagonist naloxone and
thus is independent of activation of
opioid receptors. DHCB analgesia is
unaffected by opioid receptor
antagonists. DHCB also appears to
be an effective analgesic in both
inflammatory and neuropathic pain
models without inducing tolerance with
repeated administration.
The structure of DHCB is similar to
another known alkaloid from
C. yanhusuo, l-tetrahydropalmatine
(l-THP), known to bind to dopamine
receptors. Zhang and colleagues
examined the effects of DHCB and
l-THP on dopamine receptor-
expressing cells and showed that both
compounds were potent antagonists of
dopamine receptors. DHCB has high
affinity for D2-like receptors compared
to D1-like receptors and produces less
sedative effects than l-THP at analgesic
doses. Similar to l-THP-induced
analgesia [4], DHCB analgesia is
mediated by D2 receptors. The efficacy
of DHCB was tested with multiple pain
assays, including thermal tail-flick andHargreaves tests, mechanical von Frey
test, inflammatory formalin pain test
and neuropathic pain in the spinal
nerve ligation model. The analgesic
effects of DHCB in the tail-flick test
were reversed by D2 agonists and
abolished in D2-knock-out mice,
indicating a role for D2-receptors in
modulating thermal pain.
The results are intriguing because
they support the idea that dopamine
has an important role in pain
modulation. There is a long history of
studies implicating dopamine in the
modulation of pain circuits (reviewed
in [5,6]). Electrical stimulation and
lesion of brain areas containing
dopamine neurons, such as the
substantia nigra and ventral tegmental
area, modulate pain. Transgenic
mice engineered to be deficient in
dopamine have increased sensitivity to
pain [7], suggesting that dopamine is
important in setting pain thresholds. In
humans, D2 receptor binding is
associated with pain and pain
modulatory capacity [8]. However, a
complete understanding of how
dopamine modulates pain circuits is
not understood as D1 and D2 agonists,
as well as D2 antagonists, have been
demonstrated to be analgesic
(reviewed in [5,6]). The complexity
appears to arise from variability in
dopamine actions across brain
regions, as well as the modality of pain,
which can involve different networks
[5]. Of particular interest are studies
using the atypical antipsychotic
amisulpride for effective treatment of
burning mouth pain [9] and thermal
pain in rodents [10]. Anecdotal clinical
evidence suggested for many years
that there was a role for atypical
antipsychotics in the relief of pain
for some patients. A Cochrane review
of studies focused on the effectiveness
of antipsychotics for pain concluded
that antipsychotics produced
statistically relevant effects on pain
but that many of the studies were small
and not well-standardized in pain
assessment and documentation [11].
One interesting observation is that low
doses of amisulpride are selective
antagonists of the D2 autoreceptor
[12], the receptor localized
presynaptically on dopamine terminals.
D2 autoreceptors decrease
neurotransmitter release from
dopamine terminals. These results
suggest that the analgesic action
of DHCB may be associated with
disinhibition or an increase indopaminergic and opioid
neurotransmission in the midbrain [10].
The possibility that the potent
analgesia of DHCB may be a result
of selective antagonism of D2
autoreceptors is a provocative
interpretation of the data because it
implies that selective antagonism of
G-protein-coupled receptors (GPCRs)
localized to presynaptic domains of
neurons may be useful therapeutic
targets. In addition, the hypothesis is
based on the assumption that
ligand–receptor interactions are
different and can be exploited for
differential activation or inhibition of
receptors in these different cellular
compartments. Studies have
demonstrated that receptor signaling
and modulation of opioid [13] and
adenosine [14] receptors is different in
presynaptic versus postsynaptic areas
of neurons. Indeed, it has recently been
demonstrated that the efficacy of
clozapine, an atypical antipsychotic, is
dependent on presynaptic activity of
the serotonin system [15]. However,
most structure–activity screens are
performed in cell lines expressing
GPCRs and primarily measure
changes in the soma, simulating
postsynaptic actions. Thus, it may be
that assays of presynaptic GPCR
activity are necessary to identify
compounds that preferentially target
presynaptically localized receptors.
Alternatively, the key to effective
analgesia may be the combined
action on D2 and opioid receptors
shown for both DHCB and amisulpride
[10]. The idea that drugs can be more
efficacious if they have multiple targets
or target ‘network pharmacology’ is
becoming more mainstream and
challenges the traditional drug
discovery paradigm of ‘‘one gene, one
target, one drug’’ [16]. This may be one
reason that TCM has such a
long-standing history in the treatment
of diseases.
The study by Zhang and colleagues
[3] has outlined a strategy for
identification and development of pain
therapeutics from TCM. Their results
support the feasibility of the herbalome
project to identify novel pain
therapeutics. It is clear that there are
many areas of the strategy that can
be further optimized. First, there is a
need to further develop extraction
techniques and purification
techniques. Recent advances have
allowed the extraction and
fractionation of lipid-likemolecules that
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technical advances have inspired the
‘herbalome project’ to intensely focus
on developing new extraction and
purification techniques [2]. Second,
the strategy used in the current study
was to screen fractions on mu-opioid
receptor-expressing cell lines and it
was only fortuitous that DHCB had
weak actions at the mu-opioid
receptor. Other equally efficacious
compounds may have been missed
by the selective nature of the screen.
Additional high-throughput strategies
need to be developed that also
screen compounds for their activity
at presynaptic receptors and
potentially their ability to induce
antinociception.
A remaining question is whether
target-based strategies are useful for
development of new therapeutics. This
strategy has been the predominant one
over the past 20 years and has failed
to develop sufficient new therapeutics
[18]. Reverse pharmacology is
dependent on screening known
receptor structures, even though some
of the receptors are orphan receptors
with no known endogenous ligand.
The pain community has at least
expanded their target-based approach
to include therapeutic development of
ligands that target other proteins,
including ion channels, such as TRPV1
[19], and transporters, such as the
potassium–chloride cotransporter
(KCC2) [20], for analgesia. This field is
currently exploding and it is likely that
natural compounds from TCMs will be
isolated that selectively modulate
these targets as well.References
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Step ForwardThe spindle is a micron-scale structure that assembles from nanometer-sized
tubulin building blocks. How does the spindle know what size to be? Changes
in cytoplasmic volume are shown to be sufficient to modulate the size of the
spindle.Sophie Dumont
Biological assemblies are built from
smaller building blocks. While we have
uncovered the identity of many building
blocks of life, we do not understand
what specifies the size of the structuresthey form. Yet, their size must be
carefully controlled. As kids, we
disappointingly learned that the tallest
snow fort we could build was
determined by our own height, no
matter how much snow had fallen.
Fort height was thus set by our ownintrinsic limitations, not by the
availability of snow building blocks
(in Canada, at least). In contrast, the
biggest LEGO structure we could build
was not limited by us, but by an
extrinsic factor — the number of
available LEGO blocks. What sets the
size of the biological structures
nature builds? New studies by
Good et al. [1] and Hazel et al. [2] show
that changes in cytoplasmic
volume — and likely the number of
building blocks — are sufficient to
regulate the size of a macromolecular
assembly.
Life’s basic building blocks are
nanometer-scale molecules. These
